Literature DB >> 17575387

Successful treatment of a rare complication of Henoch-Schönlein purpura in advanced age: pulmonary hemorrhage.

Ozlem Tiryaki1, Hakan Buyukhatipoglu, Metin Karakok, Celalettin Usalan.   

Abstract

Henoch-Schönlein purpura (HSP) is a form of systemic vasculitis involving both arterioles and capillaries. HSP frequently is seen in children between the ages of 2 and 11 years, though adults with this disease are occasionally encountered. Although it primarily is a disease of early childhood, it can occur at any age. The clinical manifestations include a classic tetrad: rash, arthralgias, abdominal pain and renal disease. However, it may affect almost any other bodily tissue, such as myocardium, lungs, ureter and nervous system. Pulmonary hemorrhage is a rare complication of HSP, which largely has been observed in adolescents and adults. Pulmonary hemorrhage in HSP is associated with significant morbidity and mortality. We present the successful treatment of a 78-year-old woman with HSP complicated by pulmonary hemorrhage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17575387     DOI: 10.2169/internalmedicine.46.6272

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  An adult patient with Kabuki syndrome presenting with Henoch-Schönlein purpura complicated with pulmonary hemorrhage.

Authors:  Jun Oto; Akiko Mano; Emiko Nakataki; Harutaka Yamaguchi; Daisuke Inui; Hideaki Imanaka; Masaji Nishimura
Journal:  J Anesth       Date:  2008-11-15       Impact factor: 2.078

2.  A patient with Henoch-Schönlein purpura and intra-alveolar haemorrhage.

Authors:  Nigel D Toussaint; Michael Desmond; Prue A Hill
Journal:  NDT Plus       Date:  2008-03-03

3.  Pulmonary Hemorrhaging as a Fatal Complication of IgA Vasculitis.

Authors:  Seigo Miyoshi; Tomoaki Nagao; Masayoshi Kukida; Ken-Ichi Miyoshi; Chika Namba; Sohei Kitazawa; Yukihiro Nakamura; Naohiko Hamaguchi; Jitsuo Higaki
Journal:  Intern Med       Date:  2018-06-06       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.